IOVANCE (IOVA) COO Igor Bilinsky Receives RSUs; Shares Withheld

What Happened
Igor Bilinsky, Chief Operating Officer of Iovance Biotherapeutics (IOVA), had 7,813 restricted stock units (RSUs) vest on September 8, 2026. The RSUs converted to common shares at no cash exercise price. To satisfy mandatory tax withholding, 3,976 shares were withheld by the company (not sold on the open market) at an implied per-share value of $8.70, equal to $34,591. After withholding, 3,837 shares remained issued to Bilinsky.

Key Details

• Transaction date: 2026-09-08 (reported on Form 4 filed 2026-09-10). Filing occurred within the typical two-business-day Form 4 window.
• What occurred: Conversion/settlement of 7,813 RSUs (transaction code M); 3,976 shares withheld for taxes (transaction code F).
• Prices/values: Withheld shares valued at $8.70 each, total withholding value $34,591. RSUs converted at $0 exercise price.
• Shares after transaction: 3,837 shares issued to Bilinsky after tax withholding.
• Footnotes of note: Withholding was done by the issuer to cover mandatory tax obligations (not an open-market sale). Each RSU equals one common share. Remaining RSUs from the March 5, 2025 grant will continue to vest in equal quarterly installments.

Context
This was a routine RSU vesting and company tax-withholding event (a common, non-market sale method to satisfy taxes). For derivative/award transactions like this, the reporting shows conversion of RSUs to shares rather than a cash purchase; the withheld shares simply cover tax liabilities and do not necessarily signal insider buying or selling intent.